Cadila Healthcare gains 3% on USFDA approval to market hypertension drug
USFDA has given more than 180 approvals to the Cadila Healthcare group. The group has so far filed over 310 abbreviated new drug applications since it commenced filings in FY04.
On Thursday, the Cadila Healthcare shares gained more than 3 percent intraday when it received the approval from USFDA for hypertension drug.
A wholly subsidiary of Cadila Healthcare, Zydus Pharmaceuticals (USA) Inc, has received final approval from the US Food and Drug Administration to market Nifedipine extended-release tablets.
The group manufactures the Nifedipine tablets in the strengths of 30mg, 60mg, and 90 mg.
This drug is mainly used in the treatment of hypertension (high blood pressure) and angina (chest pain).
The main manufacturing facility of the company is located at SEZ, Ahmedabad, where this drug will be produced after the approval granted by USFDA.
At present, the group embraces more than 180 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it commenced filings in FY04.
On the BSE, the stock price was quoting at Rs 429.60, up Rs 9.60, or 2.29 percent at 13:25 hours IST